These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

More than 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, ...

Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

Chronic health conditions are having a serious, negative impact on the welfare of the country's workers and their output, a ...